R-IDARAM treatment in central nervous system lymphomas: a single-center experience and review of the literature

Abstract

Introduction: Central nervous system lymphomas (CNSLs) require effective treatment strategies due to aggressive nature of disease. Despite therapeutic approaches having improved in the last decades, there is no standard treatment for these patients. As a CNSL targeted-therapy IDARAM protocol was developed, the outcomes were reported with a few studies. We observed the R-IDARAM protocol in our CNSL cases, and we discuss the effectiveness, tolerability, and toxicity with a review of the literature in this article. Subjects and Methods: We retrospectively analyzed response rates, progression-free survival, adverse events, and long-term side effects in patients who were treated by modified R-IDARAM as standard clinical care of CNSL in our hematology department. Results: Response was achieved in five of nine patients. Three patients (two primary CNSL and one secondary CNSL) are still being followed up without disease progression with a median duration of follow-up of 79 months (88, 79, and 17 months, respectively). Manageable hematological side effects including thrombocytopenia and neutropenia were experienced by all patients. Conclusion: R-IDARAM protocol may be an option with high early response rates and manageable toxicity. Hematological side effects are the main problem, and long-term neurological toxicity is not common. Eligible patients must continue with autologous stem cell transplantation due to poor long-term survival outcomes.

Keywords

Aggressive lymphomas - central nervous system lymphomas - modified R-IDARAM

• References

• 1 Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C. et al. CBTRUS Statistical Report: Primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol 2015; 17: iv1-62
• 2 Citterio G, Ferreri AJ, Reni M. Current uses of radiation therapy in patients with primary CNS lymphoma. Expert Rev Anticancer Ther 2013; 13: 1327-37
• 3 Kasenda B, Ferreri AJ, Marturano E, Forst D, Bromberg J, Ghesquieres H. et al. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—A systematic review and individual patient data meta-analysis. Ann Oncol 2015; 26: 1305-13
• 4 Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M. et al International Extranodal Lymphoma Study Group (IELSG). High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: A randomised phase 2 trial. Lancet 2009; 374: 1512-20
• 5 Fan N, Zhang L, Xu X, Chen B, Zhu C, Li P. et al. Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma. Oncotarget 2017; 8: 53701-13
• 6 Moreton P, Morgan GJ, Gilson D, Smith GM, McVerry BA, Davies JM. et al Central and Southern Lymphoma Group. The development of targeted chemotherapy for CNS lymphoma-a pilot study of the IDARAM regimen. Cancer Chemother Pharmacol 2004; 53: 324-8
• 7 Yilmaz M, Erkutlu I, Kilciksiz S, Pehlivan M, Okan V, Alptekin M. et al. Modified IDARAM chemotherapy regimen for primary central nervous system lymphoma: Experience of three cases. Hematology 2008; 13: 107-13
• 8 Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML. et al. A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group. Blood 1994; 84: 1361-92
• 9 Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W. et al. Primary central nervous system lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model. J Clin Oncol 2006; 24: 5711-5
• 10 National Cancer Institute Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events and Common Toxicity Criteria. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. [Last accessed on 2012 Oct 10]
• 11 Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD. et al. Non-Hodgkin’s lymphoma of the brain: Can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the radiation therapy oncology group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992; 23: 9-17
• 12 Blay JY, Conroy T, Chevreau C, Thyss A, Quesnel N, Eghbali H. et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998; 16: 864-71
• 13 Harder H, Holtel H, Bromberg JE, Poortmans P, Haaxma-Reiche H, Kluin-Nelemans HC. et al. Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 2004; 62: 544-7
• 14 Batchelor TT. Primary central nervous system lymphoma. Hematology Am Soc Hematol Educ Program 2016; 2016: 379-85
• 15 Ferreri AJ, Reni M, Pasini F, Calderoni A, Tirelli U, Pivnik A. et al. A multicenter study of treatment of primary CNS lymphoma. Neurology 2002; 58: 1513-20
• 16 Zeremski V, Koehler M, Fischer T, Schalk E. Characteristics and outcome of patients with primary CNS lymphoma in a “real-life” setting compared to a clinical trial. Ann Hematol 2016; 95: 793-9
• 17 Giannini C, Dogan A, Salomão DR. CNS lymphoma: A practical diagnostic approach. J Neuropathol Exp Neurol 2014; 73: 478-94
• 18 Zhao D, Qian L, Shen J, Liu X, Mei K, Cen J. et al. Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma. J Cell Mol Med 2014; 18: 1081-6
• 19 Maciocia P, Badat M, Cheesman S, D’Sa S, Joshi R, Lambert J. et al. Treatment of diffuse large B-cell lymphoma with secondary central nervous system involvement: Encouraging efficacy using CNS-penetrating R-IDARAM chemotherapy. Br J Haematol 2016; 172: 545-53
• 20 Qian L, Zhou C, Shen J, Cen J, Yin W. Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy. Oncotarget 2016; 7: 25783-90